Boston MA 淋巴瘤临床试验
34项针对 淋巴瘤的研究正在 Boston及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
招募中1/2 期
- Call for Information (Investigational Site 0026), Boston
A Phase 2 Study of Epcoritamab in Patients With Follicular Lymphoma and Marginal Zone Lymphoma Not Accomplishing a Complete Response With Upfront Therapy
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
招募中2 期
- Dana-Farber Cancer Institute, Boston
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
招募中3 期
- Tufts Medical Center, Boston
HEME Home Transfusion Program
招募中
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Resilience-Based Approach to Improve Long-term Quality of Life in Post-treatment Lymphoma Survivorship
招募中
- Mass General Hospital, Boston
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL
招募中1 期
- Brigham and Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
招募中2 期
- Massachusetts General Hospital, Boston
- Beth Israel Deaconess Medical Center, Boston
AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
招募中1/2 期
- Research Site, Boston
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
招募中1/2 期
- Dana Farber Cancer Institute, Boston
Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
招募中3 期
- Research Site, Boston
A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
招募中1 期
- Beth Israel Deaconess Medical Center - Research, Boston
Increasing Resiliency Among Early Post-Treatment Lymphoma Survivors
招募中
- Mass General Brigham, Boston
A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
招募中1/2 期
- Dana Farber Cancer Institute., Boston
Epco, Zanu, Ritux for R/R FL or MZL
招募中2 期
- Dana-Farber Cancer Institute, Boston
CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
招募中1/2 期
- Dana-Farber Cancer Institute, Boston
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
招募中1/2 期
- Massachusetts General Hospital, Boston
A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
招募中1/2 期
- Massachusetts General Hospital, Boston
Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy
招募中4 期
- Brigham and Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
DALY II USA/ MB-CART2019.1 for DLBCL
招募中2 期
- Dana Farber Cancer Institute, Boston
A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
招募中1/2 期
- Dren Investigational Site, Boston
Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
招募中观察性研究
- Dana-Farber Cancer Institute, Boston
Remote Monitoring and Symptom Management Digital Application
招募中
- Massachusetts General Hospital, Boston
Defining the Role of Palliative carE for Patients With Hematologic Malignancies Undergoing Adoptive CEllular Therapy
招募中
- Massachusetts General Hospital Cancer Center, Boston
Interrupting Sedentary Time to Improve Cardiometabolic Health and Toxicity in Patients With Lymphoma Receiving Chemotherapy: The iSTAND Trial
招募中
- Dana Farber Cancer Institute, Boston
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
招募中2 期
- Dana-Farber Cancer Institute, Boston
Odronextamab in Low Tumor Volume Advanced FL
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
A Phase II Study of Glofitamab Plus Polatuzumab-R-CHP for Patients With High-risk Diffuse Large B-cell Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana Farber Cancer Institute, Boston
BRAZAN: A Randomized Phase 2 Study of Bendamustine, Rituximab, Cytarabine (AraC) Induction With Zanubrutinib (BRAZAN) Followed by Zanubrutinib/Rituximab +/- Sonrotoclax Maintenance in Treatment-Naïve Mantle Cell Lymphoma
招募中2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
CONFIRM: Magnetic Resonance Guided Radiation Therapy
招募中
- Brigham & Women's Hospital, Boston
- Dana Farber Cancer Institute, Boston
Avo In R/R And Previously Untreated MCL
招募中1/2 期
- Beth Israel Deaconess Medical Center, Boston
- Dana-Farber Cancer Institute, Boston
Mosunetuzumab for CLL MRD Clearance
招募中1/2 期
- Brigham & Women's Hospital, Boston
- Dana-Farber Cancer Institute, Boston
A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia
招募中2 期
- Dana Farber Cancer Institute, Boston
其他城市的 淋巴瘤试验
- Houston, TX34 项研究
- New York City, NY33 项研究
- Washington, DC23 项研究
- Baldwin Park, CA22 项研究
- Chicago, IL19 项研究
- Durham, NC17 项研究
- St. Louis, MO15 项研究
- Cleveland, OH13 项研究
- Seattle, WA13 项研究
- Atlanta, GA13 项研究
- Philadelphia, PA13 项研究
- Edison, NJ12 项研究
Boston的其他研究
- 乳腺癌110 项研究
- 癌症（所有类型）90 项研究
- 非小细胞肺癌87 项研究
- 肺癌63 项研究
- 结直肠癌62 项研究
- 卵巢癌62 项研究
- 转移性癌症61 项研究
- 前列腺癌56 项研究
- 子宫内膜癌51 项研究
- 抑郁症50 项研究
- 心力衰竭46 项研究
- 多发性骨髓瘤45 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年11月15日。每项研究自行设定入选标准，由研究团队决定谁能参与。